舒肝解郁胶囊与帕罗西汀治疗帕金森病伴抑郁的疗效比较

发布时间：2018-10-22 09:27

【摘要】：目的评价舒肝解郁胶囊和帕罗西汀对帕金森病(PD)伴抑郁患者的临床疗效。方法 75例PD伴抑郁患者随机分为帕罗西汀组、舒肝解郁胶囊组和对照组,每组25例。3组均同时进行PD常规治疗,帕罗西汀组给予帕罗西汀治疗,舒肝解郁胶囊组口服舒肝解郁胶囊,均为期6周;对照组不接受任何抗抑郁药物治疗。治疗3周和6周分别以抑郁自评量表(SDS)、汉密尔顿抑郁量表(HAMD)和改良Webster症状评分量表(简称Webster评分)对3组患者进行抑郁和PD疗效评价,同时观察治疗组患者不良反应。结果治疗第3和第6周时,根据SDS评分各组有效率:对照组为8%及12%,帕罗西汀组为40%及64%,舒肝解郁胶囊组为44%及60%;根据HAMD评分各组有效率:对照组为8%及20%,帕罗西汀组为44%及72%,舒肝解郁胶囊组为44%及64%;根据Webster评分各组有效率:对照组为16%及28%,帕罗西汀组为28%及64%,舒肝解郁胶囊组为24%及60%;与对照组比较,帕罗西汀组和舒肝解郁胶囊组治疗3周和6周有效率均显著提高(P0.05);帕罗西汀组和舒肝解郁胶囊组治疗6周有效率均显著高于治疗3周,且差异具有统计学意义(P0.05);帕罗西汀组和舒肝解郁胶囊组各项评分组间比较差异均无统计学意义(P0.05)。各组患者未见明显不良反应。结论舒肝解郁胶囊治疗PD伴抑郁疗效明确,安全性好。
[Abstract]:Objective to evaluate the clinical efficacy of Shugan Jieyu capsule and paroxetine in (PD) patients with Parkinson's disease. Methods Seventy-five patients with PD with depression were randomly divided into three groups: paroxetine group, Shugan Jieyu capsule group and control group. Each group (25 cases) received routine PD therapy at the same time, and paroxetine group was treated with paroxetine. Shugan Jieyu capsule group was given Shugan Jieyu capsule for 6 weeks, while the control group was not treated with any antidepressants. Depression and PD were evaluated by (SDS), Hamilton Depression scale (HAMD) and modified Webster symptom scale (Webster) at 3 weeks and 6 weeks after treatment, respectively. The adverse reactions of the patients in the treatment group were observed at the same time. Results at the 3rd and 6th weeks of treatment, According to the SDS score, the effective rates were 8% and 12 in the control group, 40% and 64 in the paroxetine group, 44% and 60% in the Shugan Jieyu capsule group, and 8% and 20% in the control group, 44% and 72% in the paroxetine group, and 44% and 60% in the Shugan Jiayu capsule group, respectively, according to the HAMD score: 8% and 20% in the control group, 44% and 72% in the paroxetine group. According to the Webster score, the effective rates were 16% and 28% in the control group, 28% and 64% in the paroxetine group and 24% and 60% in the Shugan Jieyu capsule group, respectively. The effective rates of paroxetine group and Shugan Jieyu capsule group were significantly increased at 3 and 6 weeks (P0.05), the effective rate of paroxetine group and Shugan jiayu capsule group were significantly higher than that of 3 weeks treatment group. And the difference was statistically significant (P0.05); paroxetine group and Shugan Jieyu capsule group were not statistically significant differences between the scores (P0.05). No obvious adverse reactions were observed in each group. Conclusion Shugan Jieyu capsule is effective and safe in the treatment of PD with depression.
【作者单位】：川北医学院附属医院神经内科;
【分类号】：R742.5;R749.4

【相似文献】